NKX3.1 is a transcription factor used to identify prostatic adenocarcinomas. We describe novel functionality for NKX3.1 compared with Grocott and periodic acid-Schiff-diastase (PASD) on esophageal biopsies. We identified esophageal biopsies on the basis of the search term "candida" from March 28, 2012 to December 27, 2013. Of 85 cases for which 3 stains were available and at least 1 stain was positive for fungus consistent with Candida, 83 cases stained as positive with NKX3.1, compared with 79 with PASD and 75 with Grocott. NKX3.1 was significantly superior to Grocott but not to PASD (P<0.05). NKX3.1 was significantly more efficacious in leading to a positive diagnosis of esophageal candidiasis compared with Grocott, resulting in a significantly higher number of positive fragments per slide as well as the number of organisms per fragment, but not PASD. NKX3.1 will be useful to add to the stain armamentarium for Candida and possibly other fungal organisms.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PAI.0000000000000528 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Symptomatic Benign Prostatic Hyperplasia with Suppressed Epigenetic Regulator HOXB13 Shows a Lower Incidence of Prostate Cancer Development.
Cancers (Basel)
January 2024
Division of Urologic Surgery, Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA.
Our objective was to identify variations in gene expression that could help elucidate the pathways for the development of prostate cancer (PCa) in men with Benign Prostatic Hyperplasia (BPH). We included 98 men with BPH, a positive prostate MRI (Prostate Imaging Reporting and Data System; PIRADS ≥ 4), and a negative biopsy from November 2014 to January 2018. RNA sequencing (RNA-Seq) was performed on tissue cores from the MRI lesion and a geographically distant region (two regions per patient).
View Article and Find Full Text PDFAssociation between copy number alterations estimated using low-pass whole genome sequencing of formalin-fixed paraffin-embedded prostate tumor tissue and cancer-specific clinical parameters.
Sci Rep
December 2023
Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark.
Copy number alterations (CNAs) are frequently observed in early-stage prostate cancer and are associated with disease recurrence and tumor aggressiveness. Cost-effective assessment of CNAs could enhance clinical utility of CNAs. Here, we combined the cost-effectiveness of low-pass (low coverage) whole genome sequencing (LPWGS) and the routine availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue for assessing CNAs in a cohort of 187 men with early-stage localised prostate cancer.
View Article and Find Full Text PDFCorrelated with better prognosis, CSTA inhibits metastasis of nasopharyngeal carcinoma cells via suppressing AKT signaling through promoting METTL3 degradation.
Biochim Biophys Acta Mol Basis Dis
June 2023
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China; Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou 510060, China. Electronic address:
Article Synopsis
- Cystatin A (CSTA) levels are lower in metastatic nasopharyngeal carcinoma (NPC) tissues, and reduced CSTA correlates with worse survival outcomes for patients.
- CSTA inhibits NPC cell movement and metastasis by affecting the AKT signaling pathway, which is crucial for cell motility.
- The interaction between CSTA and METTL3 leads to the degradation of negative regulators NKX3-1 and LHPP, suggesting that targeting the CSTA-METTL3-NKX3-1/LHPP-AKT pathway could provide new treatment options for NPC metastasis.
An Allelic Variant Can Affect Biochemical Relapse in Prostate Cancer Patients.
Anticancer Res
January 2023
Laboratório de Mutagênese e Oncogenética, Departamento de Biologia Geral, Universidade Estadual de Londrina, Paraná, Brazil;
Background/aim: Prostate cancer (PCa) is one of the most frequent neoplasms in men around the world. In recent years, the search for new biomarkers with greater prognostic potential for PCa has intensified. This study aimed to evaluate single nucleotide polymorphisms (SNPs) and a combined panel of these polymorphisms in relation to biochemical recurrence in patients who were through prostatectomy, with an average of 7 years of follow-up.
View Article and Find Full Text PDF5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
J Pathol
April 2022
Department of Urology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Article Synopsis
- Benign prostatic hyperplasia (BPH) is a condition where the prostate gland gets bigger as men get older, causing urinary issues.
- Men with BPH often take medicine called 5-alpha reductase inhibitors (5ARIs) to help shrink the enlarged prostate and improve their symptoms.
- Researchers discovered that while 5ARI treatment can help, some prostate cells change and survive in different ways, leading to varied responses, and sometimes, men may still need surgery for relief.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!